Cite
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC.
MLA
Scott, Ryan. “Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC.” Targeted Therapies in Oncology, vol. 13, no. 6, May 2024, pp. 49–50. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=177144906&authtype=sso&custid=ns315887.
APA
Scott, R. (2024). Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC. Targeted Therapies in Oncology, 13(6), 49–50.
Chicago
Scott, Ryan. 2024. “Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC.” Targeted Therapies in Oncology 13 (6): 49–50. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=177144906&authtype=sso&custid=ns315887.